TrialArthritis research & therapy2016

Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study.

Anne C Bay-Jensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.